Abstract
Biomarkers are considered as an innovative tool in the diagnosis and follow-up of breast cancer. The aim of the study was to assess the profile of circulating tumour markers CA 15-3 and CEA in patients under chemotherapy for breast cancer in Ouagadougou. This is a prospective cross-sectional study with a descriptive and analytical aims which was done from July to November 2020. Patients with histologically confirmed malignant breast tumour and under chemotherapy were included. Results revealed that the study was on thirty (30) female patients whose average age was 47.47 ± 2.10 years with a mean BMI of 27.29 ± 1.09 kg/m2. It was a non-specific type of infiltrating carcinoma with SBRm II grade in 90% of the patients. The mean CA 15-3 was 212.98 U/mL before chemotherapy and 165.75 U/mL after it. The CEA mean value was 3.13 ng/L before chemotherapy and 16.14 ng/L after it. Serum CA 15-3 was significantly associated with tumour site, SBRm grade, chemotherapy line and treatment response. Serum CEA level was significantly associated with tumour site and SBRm grade. Despite their lack of sensitivity, tumour markers, particularly CA 15-3 enabled assessment of the response to treatment in patients in this study. Key words: Tumour markers, CA 15-3, CEA, breast cancer, chemotherapy.
Highlights
In Burkina Faso, breast cancer is responsible for 17.7% of cancer-related deaths in women
Patients were selected in collection centres after file study among patients under chemotherapy for breast cancer and meeting the following criteria: histologically confirmed breast malignancy; patients with at least four courses of treatment allowing assessment of chemotherapy efficiency; complete clinical record; being aged at least 18 years and have given their free and informed consent to participate in the study
As the most common malignancy in women, breast cancer is a great threat for women's health worldwide
Summary
In Burkina Faso, breast cancer is responsible for 17.7% of cancer-related deaths in women. It constitutes an important component of effective care for breast cancer: given to patients at an early stage, it has a good impact on survival and contributes to cure. It is essential to identify reliable prognostic factors to guide decision-making during the treatment of breast cancer in order to improve prognosis. The concentration of circulating marker detected in the biological fluid is an indirect estimator of tumour mass or tumour aggressiveness; allowing the assessment of tumour progression and/or therapeutic efficacy (Uygur and Gümüş, 2021)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
